Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer

Acta Oncologica

Volumn 44, Issue 2, 2005, Pages 134-141

  Sawada, Shojiro ^a   Sato, Kazuhiko ^a   Kusuhara, Masatoshi ^a   Ayaori, Makoto ^a   Yonemura, Atsushi ^a   Tamaki, Kuniyoshi ^a   Hiraide, Hoshio ^a   Mochizuki, Hidetaka ^a   Ohsuzu, Fumitaka ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CHOLESTEROL; EXEMESTANE; FADROZOLE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EARLY CANCER; ENZYME ACTIVITY; FEMALE; HUMAN; JAPAN; LIPID METABOLISM; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTRADIOL; FEMALE; HUMANS; JAPAN; LIPIDS; LIPOPROTEIN LIPASE; MIDDLE AGED; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 17144430927     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510007585     Document Type: Article

References (39)

1. Howell A, Dowsett M. Recent advances in endocrine therapy of breast cancer. Br Med J 1997;315:863-6.
2. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocrine Rev 1990;11:221-65.
3. Murphy MJ. Molecular action and clinical relevance of aromatase inhibitors. Oncology 1998;3:129-30.
4. Dowsett M. Aromatase inhibitors come of age. Ann Oncol 1997;8:631-2.
5. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
6. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatization and plasma oestrogen levels in post-menopausal women with breast cancer. Br J Cancer 1996;74:1286-91.
7. Buzdar AU, Robertson JFR, Eiermann W, Nabholtz J-M. An overview of the pharmacology of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002;95:2006-16.
8. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of North American Multicenter randomized trial. J Clin Oncol 2000;18:3758-76.
9. Bonneterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000;18:3748-57.
10. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;395:2131-9.
11. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: results of the ATAC trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
12. Sacks FM, Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 1994;5:236-40.
13. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10.
14. Larosa JC. Management of postmenopausal women who have hyperlipidemia. Am J Med 1994;96:19S-24S.
15. Obata T, Ito T, Yonemura A, Ayaori M, Nakamura H, Ohsuzu F. R192Q paraoxonase gene variant is associated with a change in HDL-cholesterol level during dietary caloric restriction in nondiabetic healthy males. J Atheroscler Thromb 2003;10:57-62.
16. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
17. Iso H, Naito Y, Sato S, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001;153:490-9.
18. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15.
19. Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2000;20:830-5.
20. Li Z, McNamara JR, Fruchart JC, et al. Effect of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. J Lipid Res 1996;37:1886-96.
21. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641-6.
22. Angelin B, Olivecrona H, Reihner E, et al. Hepatic cholesterol metabolism in estrogen-treated men. Gastroenterogy 1992;103:1657-63.
23. Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang YF. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke 2001;32:1104-11.
24. McNamara JR, Shah PK, Nakajima K, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001;154:229-36.
25. Kinnunen PKJ, Vitranen JA, Vaino P. Lipoprotein lipase and hepatic endothelial lipase: their roles in plasma lipoprotein metabolism. Atheroscler Rev 1983;11:65-105.
26. Iverius PH, Brunzell JD. Relationship between lipoprotein lipase activity and plasma sex steroid level in obese women. J Clin Invest 1988;82:1106-12.
27. Reitman JS, Kosmakos FC, Howard BV, Taskinen MR, Kuusi T, Nikkila EA. Characterization of lipase activities in obese Pima Indians decreases with weight reduction. J Clin Invest 1982;70:791-7.
28. Tall AR, Green PH, Glickman RM, Riley JW. Metabolic fate of chylomicron phospholipids and apoproteins in the rat. J Clin Invest 1979;64:977-89.
29. Dewar J, Nabholtz J-M, Bonneterre J. The effect of anastrozole (Arimidex) on serum lipids: data from a randomized comparison of anastrozole (AN) versus tamoxifen (TAM) in postmenopausal women with advanced breast cancer (ABC). Breast Cancer Res Treat 2001;69:224 [Abstract 164].
30. Elisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001;37:1510-3.
31. Lohrisch C, Paridaens R, Dirix LY, et al. No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (R) (exemestane (E)) in the 1st-line treatment of metastatic breast cancer (MBC): companion study to an EORTC trial. Proc American Society Clinical Oncology 2001;20(Pt 1):43a, [Abstract 167].
32. Engan T, Krane J, Johannessen DC, Kvinnsland S. Plasma changes in breast cancer patients during endocrine therapy-lipids measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 1995;36:287-97.
33. Kataja V, Hietanen P, Joensuu H, et al. The effects of adjuvant anastrozole, exemestane, tamoxifen and toremifene on serum lipids in postmenopausal women with breast cancer-a randomised study. Breast Cancer Res Treat 2002;76:S156 [Abstract 634].
34. Costa LA, Kopreski MS, Demers LM, et al. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS16949A) in postmenopausal women with breast carcinoma. Cancer 1999;85:100-3.
35. Windler E, Kovarten PT, Caos YS, Brown MS, Havel RJ, Goldstein JL. The estradiol stimulated lipoprotein receptor of rat liver: a binding site that mediates uptake of rat lipoproteins containing apoprotein B and E. J Biol Chem 1980;255:10464-71.
36. Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-9.
37. Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998;83:1633-5.
38. Applebaum-Bowden D, McLean P, Steinmetz A, et al. Lipoprotein, apolipoprotein, and lipolytic enzymes following estrogen administration in postmenopausal women. J Lipid Res 1989;30:1895-906.
39. Tikkanen MJ, Nikkila EA. Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am Heart J 1987;113:562-7.